Compare moats

The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion.

source: sec.gov

Cipher (renamed Cipher Digital Inc. on 20 February 2026) holds signed, credit-supported leases but has not yet shown that they amount to a durable advantage. Its 2025 Form 10-K (filed 2026-02-24) says "Through the end of 2025, our revenue has been derived from mining bitcoin". Its Q2 2026 business update (2026-08-04, Exhibit 99.1, https://www.sec.gov/Archives/edgar/data/1819989/000181998926000038/q226_earningsxprxdraftxvf.htm) reported "Q2 2026 Revenue of $25 million", and its first HPC rent began only in August 2026 at Black Pearl. The 10-K's own risk factors describe a contested market. They say "There has been an increasing number of businesses constructing HPC data centers, which has resulted in increasing competition and pricing pressure that may cause us to reduce our pricing in order to remain competitive", that "our data centers are single-tenant properties", and that lessees "will have the right to terminate the lease if there are significant delays in the completion of construction". At Barber Lake, where the 10-K targeted Phase I delivery "by September 30, 2026", a September 2026 amendment, made "In connection with change orders and the continued evolution of tenant requirements", moved data-hall deliveries to the fourth quarter of 2026 through the first quarter of 2027. Under it, Cipher "will bear the first $359.3 million of costs in excess of the initial budgeted amount" (2026-09-25). There is real counter-evidence: a 15-year Amazon lease, a Google-backstopped Fluidstack lease whose contracted life a "leading AI lab" extended to 20 years, and a third lease with an investment-grade hyperscale tenant. Until that capacity is delivered and paying rent, though, a moat is not shown, so the band is none.

source: sec.gov

Nova is gaining share and earning steady margins, but in a market another vendor dominates. On the Q1 2026 call (2026-05-14, https://www.investing.com/news/transcripts/earnings-call-transcript-nova-semiconductors-beats-q1-2026-forecasts-stock-rises-93CH-4688858), the CEO said 'The latest Gartner market share report' shows 'an additional 400 basis points share gain in Film SIMS and critical dimension metrology', the 'second consecutive year of significant share growth, cementing Nova's position as this market's second-largest vendor'. The 2025 20-F (filed 2026-02-17) says Nova's product revenues grew at a CAGR of approximately 27.5% over 2020-2025, while Gartner estimates the process-control sector's CAGR at approximately 16.0%. Gross margin was 57.4% in 2025 and 57.6% in 2024. But the leader is KLA: Castellano of The Information Network (2025-09-10) writes that his non-metal thin film share table shows how KLA 'has entrenched its dominance' and how Nova 'has built a steady secondary position'. The 20-F also warns that 'a number of patents which relate to our main-stream products have already expired or are expected to expire in the coming years', which 'may add significant competition'. One customer took 23% of 2025 revenue and China 33%. Durable but second-place, so narrow.

source: sec.gov

The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power."

source: sec.gov

No moat source is demonstrated yet. Switching costs are the most likely candidate, since the leases are long (15 years at Black Pearl; Barber Lake now a 20-year contracted life) and each site has a single tenant. But the 10-K says tenant guarantees "will only be effective after rent commencement under such leases and are subject to certain limitations", and by August 2026 rent had begun at only one site. The advantages the 10-K claims are the company's own. It speaks of "industry-leading expertise in originating and securing industrial-scale, greenfield data center sites" and of securing West Texas land "on more favorable terms than in more established data center markets". The same document says "there is significant competition for power capacity and energized facilities". Intellectual property is modest: "four granted United States patents and one issued patent in Taiwan". With 66 full-time employees, Cipher has no scale advantage over the competitors it names: CoreWeave, Digital Realty, Equinix, Vantage Data Centers and Aligned Data Centers.

source: sec.gov

The 20-F grounds Nova's position in measurement technology and know-how. Its patents cover optical measurement, integrated process-control concepts, X-ray measurement systems and chemical metrology, and it says 'Our in-house know-how is an important element of our intellectual property', adding that 'duplication of this coordination by competitors or individuals seeking to copy our products would be difficult' and that 'most of the core technology operating on our systems is not exposed to a user or to our competitors'. R&D staff numbered about 682, approximately 163 with Ph.D.s. Switching friction is real too: the 20-F says that once a manufacturer selects a vendor's equipment it 'generally relies upon that equipment for the specific production line application and frequently will attempt to consolidate its other capital equipment requirements with the same vendor'. But Nova is the share gainer against an incumbent, which points to technology rather than lock-in as the primary source. Patent expiries on main-stream products are a stated weakness.

source: sec.gov

The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date."

source: sec.gov

No independent share or rank was found. The 10-K names CoreWeave, Digital Realty, Equinix, Vantage Data Centers and Aligned Data Centers as competitors, along with miners that have "signed leases with hyperscalers and HPC tenants": Hut 8, IREN, TeraWulf, Core Scientific and Applied Digital. Cipher has signed hyperscale-grade tenants (Amazon; Fluidstack with a Google backstop; a third investment-grade hyperscaler) but delivered its first HPC capacity only in August 2026 (Q2 2026 update). That makes it a fast follower. Its self-description as "a leading developer, owner, and operator of industrial-scale data centers" is the company's own claim and is not counted.

source: sec.gov

The share evidence puts Nova second. On the Q1 2026 call the CEO said the latest Gartner market share report cements Nova's 'position as this market's second-largest vendor' in film and critical dimension metrology. That ranking comes from Gartner but reaches us through Nova's own call. Castellano (The Information Network, 2025-09-10, https://drrobertcastellano.substack.com/p/onto-innovations-strategic-drift) independently writes that his non-metal thin film share table shows how KLA 'has entrenched its dominance' and how Nova 'has built a steady secondary position'. Nova is stronger in sub-segments: SemiAnalysis (2022-09-06) writes that Nova has 'a high share in integrated optical critical dimension (OCD) inspection tools and materials metrology tools', though 'little success outside these sub-segments'.

source: sec.gov

Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries."

source: sec.gov

The 10-K says competition "has resulted in increasing competition and pricing pressure that may cause us to reduce our pricing in order to remain competitive". It adds that if customers cut usage "we may be compelled to lower our prices or risk losing a significant customer". At Barber Lake, Cipher agreed to absorb "the first $359.3 million of costs in excess of the initial budgeted amount", with the tenant reimbursing "50% of any such costs above that amount" (2026-09-25, Exhibit 99.1, https://www.sec.gov/Archives/edgar/data/1819989/000181998926000043/barberlakeleaseamendmentpr.htm). Its one input-cost edge is specific to mining: Odessa's power costs about 2.8 c/kWh under the Luminant contract, available "until at least July 2027". A landlord that concedes cost overruns to its tenants has weak pricing power.

source: sec.gov

Gross margin was 57.4% in 2025 and 57.6% in 2024 (Q4 2025 release), 57.7% in Q1 2026 and 56.5% in Q2 2026 (Q2 2026 release, https://www.novami.com/investors/press-releases/nova-reports-record-second-quarter-2026-financial-results/). The 20-F credits the shift to selling directly to chipmakers with improving 'our products gross margins and net profitability'. Buyers are concentrated: the five largest customers took 51% of 2025 revenue, with Customer A at 23%, and the 20-F warns that dependence on 'few process control product lines' exposes Nova to anything 'adversely affecting the pricing' of those lines.

source: sec.gov

A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish.

Cipher develops single-tenant, powered data-centre campuses for hyperscale and AI tenants: Amazon at Black Pearl, Fluidstack (backstopped by Google) at Barber Lake, and an unnamed investment-grade hyperscaler at a third campus. Meanwhile it winds down bitcoin mining.

Upstream metrology supplier to logic, foundry, memory and packaging chipmakers, selling directly to manufacturers. Its integrated systems are built into process tools. China was 33%, Taiwan 29% and Korea 16% of 2025 revenue.

• Intismeran autogene (mRNA-4157) Unknown · Moderate source: sec.gov
• Spikevax Top 3 · Moderate source: sec.gov
• mNEXSPIKE Top 3 · Moderate source: sec.gov
• mRESVIA Challenger · Moderate source: sec.gov
• mRNA-1010 seasonal influenza vaccine Unknown · Moderate source: sec.gov

• Bitcoin mining (Odessa) Unknown · Low source: sec.gov
• HPC data center leasing (Black Pearl, Barber Lake, Stingray) Challenger · Moderate source: sec.gov

• Advanced-packaging dimensional metrology (Sentronics, Nova WMC) Challenger · Low source: sec.gov
• Chemical metrology (Ancolyzer, AncoScene, DMR) Top 3 · Moderate source: novami.com
• Integrated metrology (Nova i-platform) Top 3 · Moderate source: newsletter.semianalysis.com
• Materials metrology (VeraFlex, Metrion, Elipson) Top 3 · Moderate source: marketbeat.com
• Standalone dimensional metrology (Nova Prism, T-platform, VeloCD, MMSR) Top 3 · Moderate source: investing.com

Editorial prior, not backtested.

see exactly how it voted →

Editorial prior, not backtested.

see exactly how it voted →

Editorial prior, not backtested.

see exactly how it voted →